Loading...
•
Mar 31, 2023
Blueprint Medicines Q1 2023 Earnings Report
Blueprint Medicines reported first quarter 2023 results, achieving significant revenue and progress in systemic mastocytosis.
Key Takeaways
Blueprint Medicines reported strong AYVAKIT revenue growth and progress in expanding its impact and transforming outcomes for patients. The company achieved $39.1 million in AYVAKIT/AYVAKYT net product revenues and $63.3 million in total revenues in Q1 2023. They are raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST.
Achieved $39.1 million in AYVAKIT/AYVAKYT net product revenues in Q1 2023.
Total revenues reached $63.3 million in Q1 2023.
Raised 2023 AYVAKIT net product revenue guidance to $135 million to $145 million.
FDA target action date for AYVAKIT supplemental new drug application for indolent SM is May 22, 2023.
Forward Guidance
Blueprint Medicines anticipates approximately $135 million to $145 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations in 2023. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...